Axsome Therapeutics, Inc

Axsome's RSI of 73.2 signals overbought territory, yet the $9.1B valuation on a pharmaceutical company trading without traditional P/E guidance suggests the market is pricing in significant future revenue expectations rather than current earnings. The absence of a meaningful P/E ratio indicates either recent profitability inflection or continued losses despite the rally. With RSI this elevated, the stock has limited room to run without a consolidation, creating vulnerability to profit-taking if near-term catalysts disappoint. Biotech valuations hinge entirely on pipeline success; Axsome's extended move higher appears already priced for execution.